- Home
- MYGN vs GGN Comparison
MYGN vs GGN Comparison
Compare MYGN & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GGN
- Stock Information
- Founded
- MYGN 1991
- GGN 2005
- Country
- MYGN United States
- GGN United States
- Employees
- MYGN N/A
- GGN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GGN Finance/Investors Services
- Sector
- MYGN Health Care
- GGN Finance
- Exchange
- MYGN Nasdaq
- GGN Nasdaq
- Market Cap
- MYGN 744.7M
- GGN 669.1M
- IPO Year
- MYGN 1995
- GGN N/A
- Fundamental
- Price
- MYGN $4.92
- GGN $4.47
- Analyst Decision
- MYGN Hold
- GGN
- Analyst Count
- MYGN 15
- GGN 0
- Target Price
- MYGN $15.14
- GGN N/A
- AVG Volume (30 Days)
- MYGN 2.1M
- GGN 397.4K
- Earning Date
- MYGN 08-05-2025
- GGN 01-01-0001
- Dividend Yield
- MYGN N/A
- GGN 10.26%
- EPS Growth
- MYGN N/A
- GGN N/A
- EPS
- MYGN N/A
- GGN N/A
- Revenue
- MYGN $831,300,000.00
- GGN N/A
- Revenue This Year
- MYGN N/A
- GGN N/A
- Revenue Next Year
- MYGN $6.68
- GGN N/A
- P/E Ratio
- MYGN N/A
- GGN N/A
- Revenue Growth
- MYGN 7.38
- GGN N/A
- 52 Week Low
- MYGN $3.81
- GGN $3.51
- 52 Week High
- MYGN $29.30
- GGN $3.91
- Technical
- Relative Strength Index (RSI)
- MYGN 46.03
- GGN 64.52
- Support Level
- MYGN $4.78
- GGN $4.39
- Resistance Level
- MYGN $5.29
- GGN $4.50
- Average True Range (ATR)
- MYGN 0.32
- GGN 0.04
- MACD
- MYGN 0.11
- GGN -0.00
- Stochastic Oscillator
- MYGN 60.98
- GGN 76.67
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.